Sugi Predict

Sugi Predict / Compounds / SCHEMBL7149024

SCHEMBL7149024

SCHEMBL7149024

O=C[C@@H](OC(=O)c1ccccc1)[C@@H](O)[C@@H](O)CO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.49
▸ TP53 P04637 1/20 0.49
▸ PRKCA P17252 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.46
▸ CYP2D6 P10635 2/20 0.40
▸ LMNA P02545 4/20 0.39
▸ F2 P00734 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.38
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ POLB P06746 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347962 1.00 TSHR (0.49) TSHRTP53PRKCAALDH1A1CYP2D6
SCHEMBL27671082 1.00 TSHR (0.49) TSHRTP53PRKCAALDH1A1CYP2D6
SCHEMBL21798546 0.95 TSHR (0.47) TSHRTP53PRKCAALDH1A1CYP2D6
SCHEMBL2355030 0.95 TSHR (0.47) TSHRTP53PRKCAALDH1A1CYP2D6
SCHEMBL16271188 0.95 TSHR (0.47) TSHRTP53PRKCAALDH1A1CYP2D6
Bromide SCHEMBL8072032 0.94 TSHR (0.46) TSHRTP53PRKCAALDH1A1CYP2D6
SCHEMBL27671072 0.91 TSHR (0.51) TSHRTP53PRKCAALDH1A1CYP2D6
SCHEMBL30426029 0.85 ALOX15 (0.39) TSHRPRKCAALDH1A1NPC1RAB9A
SCHEMBL30295382 0.85 TDP1 (0.41) PRKCAALDH1A1LMNATDP1KMT2A
SCHEMBL7149086 0.85 TDP1 (0.41) PRKCAALDH1A1LMNATDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699240-A2 ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPEUTIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME Université Nice Sophia Antipolis (FR) 2014-02-26 — — EP claimed
WO-2012143624-A2 ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPEUTIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) 2012-10-26 — — WO claimed
US-6552183-B1 Moncyclic L-nucleosides analogs ICN PHARMACEUTICALS, INC. 2003-04-22 — — US disclosed
EP-1302474-A1 Monocyclic L-nucleosides, analogs and uses thereof Ribapharm, Inc. (US) 2003-04-16 — — EP disclosed
US-20030018186-A1 Monocyclic L-nucleosides, analogs and uses thereof BAUSCH HEALTH COMPANIES INC. (CA) 2003-01-23 — — US disclosed
EP-1254911-A1 Monocyclic L-nucleosides, analogs and uses thereof ICN Pharmaceuticals, Inc. (US) 2002-11-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018186-A1 Monocyclic L-nucleosides, analogs and uses thereof PNP, TYMP, SLC29A1 TSHR 3786/4885TP53 1942/4885PRKCA 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.